VasoRx, Inc.
- Biotech or pharma, therapeutic R&D
First-in-class proprietary nanoparticle RNAi agents for cardiovascular diseases, including atherosclerosis, pulmonary hypertension, transplant vasculopathy (graft stenosis), and arteriovenous (AV) shunt; seeking partnerships and equity investment
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}